Evidence map›Paper›PMID 37720086›Full record

ArticleiScience2023

Lethal adulthood myelin breakdown by oligodendrocyte-specific Ddx54 knockout.

Hiroaki Oizumi, Yuki Miyamoto, Chika Seiwa, Masahiro Yamamoto, Nozomu Yoshioka, Seiichi Iizuka, Tomohiro Torii, Katsuya Ohbuchi, Kazushige Mizoguchi, Junji Yamauchi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hiroaki OizumiTsumura Kampo Laboratories, Tsumura & Co, Ami, Ibaraki 300-1192, Japan.
Yuki MiyamotoDepartment of Pharmacology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo 157-8535, Japan.
Chika SeiwaGlovia Myelin Research Institute, Tsurumi-ku, Yokohama, Kanagawa 230-0046, Japan.
Masahiro YamamotoTsumura Kampo Laboratories, Tsumura & Co, Ami, Ibaraki 300-1192, Japan.
Nozomu YoshiokaDivision of Neurobiology and Anatomy, Graduate School of Medical and Dental Sciences, Niigata University, Chuo-ku, Niigata 951-8510, Japan.
Seiichi IizukaTsumura Kampo Laboratories, Tsumura & Co, Ami, Ibaraki 300-1192, Japan.
Tomohiro ToriiLaboratory of Ion Channel Pathophysiology, Graduate School of Brain Science, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan.
Katsuya OhbuchiTsumura Kampo Laboratories, Tsumura & Co, Ami, Ibaraki 300-1192, Japan.
Kazushige MizoguchiTsumura Kampo Laboratories, Tsumura & Co, Ami, Ibaraki 300-1192, Japan.
Junji YamauchiDepartment of Pharmacology, National Research Institute for Child Health and Development, Setagaya-ku, Tokyo 157-8535, Japan.
Hiroaki AsouGlovia Myelin Research Institute, Tsurumi-ku, Yokohama, Kanagawa 230-0046, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a leading disease that causes disability in young adults. We have previously shown that a DEAD-box RNA helicase Ddx54 binds to mRNA and protein isoforms of myelin basic protein (MBP) and that Ddx54 siRNA blocking abrogates oligodendrocyte migration and myelination. Herein, we show that MBP-driven Ddx54 knockout mice (

Indexed as

Biological sciencesMolecular neuroscienceNeuroscience

Identifiers

PMID37720086
PMCPMC10502337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.